
The French drugmaker is assessing a deal that could take weeks, as investors await an acquisition to bolster its medicine pipeline.
Sanofi is considering an acquisition of U.S. biotech company Insmed that could be worth more than $30 billion, according to Il Sole 24 Ore. The evaluation could take weeks, the newspaper reported.
Insmed shares initially jumped 24% on the reports, according to the article. As of 20:51 UTC on Nov. 19, they were trading at $144.47, up 20.59% from the previous close. Sanofi shares closed in Paris down 2.85%, according to the article.
The potential deal fits Sanofi’s stated aim of using acquisitions to strengthen its portfolio. The company faces the eventual loss of exclusivity for its leading drug Dupixent early in the next decade.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.